ID

22928

Descripción

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00277316

Link

https://clinicaltrials.gov/show/NCT00277316

Palabras clave

Versiones (1)
  1. 16/6/17 16/6/17 -
Subido en

16 de junio de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Renal Cell Carcinoma NCT00277316

Inglés

Eligibility Renal Cell Carcinoma NCT00277316

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
males and females with histologically confirmed metastatic clear cell rcc
Descripción

Clear-cell metastatic renal cell carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2931852
measurable disease according to response criteria for solid tumors (recist)
Descripción

Measurable Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1513041
no prior systemic cytotoxic chemotherapy
Descripción

Cytotoxic Chemotherapy Systemic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C0205373
subjects who have received either no prior therapy for rcc, systemic immunotherapy only (such as interleukin-2 or interferon), or one agent targeting vegf or a vegfr (eg, bevacizumab, sorafenib, or sunitinib malate) may be enrolled
Descripción

Renal Cell Carcinoma untreated | Immunotherapy Systemic | Interleukin-2 therapy | Interferon therapy | Pharmaceutical Preparation Targeting Vascular Endothelial Growth Factors | Pharmaceutical Preparation Targeting Vascular Endothelial Growth Factor Receptor | bevacizumab | sorafenib | sunitinib malate

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007134
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0021083
UMLS CUI [2,2]
C0205373
UMLS CUI [3]
C0199975
UMLS CUI [4]
C0279030
UMLS CUI [5,1]
C0013227
UMLS CUI [5,2]
C1521840
UMLS CUI [5,3]
C1256770
UMLS CUI [6,1]
C0013227
UMLS CUI [6,2]
C1521840
UMLS CUI [6,3]
C0148199
UMLS CUI [7]
C0796392
UMLS CUI [8]
C1516119
UMLS CUI [9]
C1700685
ecog performance status of 0 or 1
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy ≥3 months
Descripción

Life Expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
adequate organ and marrow function
Descripción

Organ function | Bone Marrow function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0678852
UMLS CUI [2,1]
C0005953
UMLS CUI [2,2]
C0031843
no other malignancies within 5 years
Descripción

Malignant Neoplasms Other Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205394
UMLS CUI [1,3]
C0332197
signed informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
radiation to ≥25% of bone marrow within 30 days of xl999 treatment
Descripción

Therapeutic radiology procedure Bone Marrow Percentage | XL999

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
UMLS CUI [2]
C1541529
subjects who have received systemic anticancer therapy within 30 days of xl999 treatment
Descripción

cancer treatment Systemic | XL999

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205373
UMLS CUI [2]
C1541529
subjects who have not recovered to grade ≤1 or to within 10% of baseline from adverse events due to medications administered >30 days prior to study enrollment
Descripción

Pharmaceutical Preparations Resulting in Adverse event CTCAE Grades | Recovery Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0332294
UMLS CUI [1,3]
C0877248
UMLS CUI [1,4]
C1516728
UMLS CUI [2,1]
C2004454
UMLS CUI [2,2]
C0332197
history of or known brain metastases, current spinal cord compression or carcinomatous meningitis
Descripción

Metastatic malignant neoplasm to brain | Compression of spinal cord | Meningeal Carcinomatosis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2]
C0037926
UMLS CUI [3]
C0220654
uncontrolled and/or intercurrent illness
Descripción

Illness Uncontrolled | Comorbidity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0009488
pregnant or breastfeeding females
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
known hiv
Descripción

HIV Infection

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019693
Volver a la parte superior de la página

Similar models

Eligibility Renal Cell Carcinoma NCT00277316

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Clear-cell metastatic renal cell carcinoma
Item
males and females with histologically confirmed metastatic clear cell rcc
boolean
C2931852 (UMLS CUI [1])
Measurable Disease
Item
measurable disease according to response criteria for solid tumors (recist)
boolean
C1513041 (UMLS CUI [1])
Cytotoxic Chemotherapy Systemic
Item
no prior systemic cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Renal Cell Carcinoma untreated | Immunotherapy Systemic | Interleukin-2 therapy | Interferon therapy | Pharmaceutical Preparation Targeting Vascular Endothelial Growth Factors | Pharmaceutical Preparation Targeting Vascular Endothelial Growth Factor Receptor | bevacizumab | sorafenib | sunitinib malate
Item
subjects who have received either no prior therapy for rcc, systemic immunotherapy only (such as interleukin-2 or interferon), or one agent targeting vegf or a vegfr (eg, bevacizumab, sorafenib, or sunitinib malate) may be enrolled
boolean
C0007134 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C0199975 (UMLS CUI [3])
C0279030 (UMLS CUI [4])
C0013227 (UMLS CUI [5,1])
C1521840 (UMLS CUI [5,2])
C1256770 (UMLS CUI [5,3])
C0013227 (UMLS CUI [6,1])
C1521840 (UMLS CUI [6,2])
C0148199 (UMLS CUI [6,3])
C0796392 (UMLS CUI [7])
C1516119 (UMLS CUI [8])
C1700685 (UMLS CUI [9])
ECOG performance status
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy ≥3 months
boolean
C0023671 (UMLS CUI [1])
Organ function | Bone Marrow function
Item
adequate organ and marrow function
boolean
C0678852 (UMLS CUI [1])
C0005953 (UMLS CUI [2,1])
C0031843 (UMLS CUI [2,2])
Malignant Neoplasms Other Absent
Item
no other malignancies within 5 years
boolean
C0006826 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Informed Consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Therapeutic radiology procedure Bone Marrow Percentage | XL999
Item
radiation to ≥25% of bone marrow within 30 days of xl999 treatment
boolean
C1522449 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C1541529 (UMLS CUI [2])
cancer treatment Systemic | XL999
Item
subjects who have received systemic anticancer therapy within 30 days of xl999 treatment
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1541529 (UMLS CUI [2])
Pharmaceutical Preparations Resulting in Adverse event CTCAE Grades | Recovery Absent
Item
subjects who have not recovered to grade ≤1 or to within 10% of baseline from adverse events due to medications administered >30 days prior to study enrollment
boolean
C0013227 (UMLS CUI [1,1])
C0332294 (UMLS CUI [1,2])
C0877248 (UMLS CUI [1,3])
C1516728 (UMLS CUI [1,4])
C2004454 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Metastatic malignant neoplasm to brain | Compression of spinal cord | Meningeal Carcinomatosis
Item
history of or known brain metastases, current spinal cord compression or carcinomatous meningitis
boolean
C0220650 (UMLS CUI [1])
C0037926 (UMLS CUI [2])
C0220654 (UMLS CUI [3])
Illness Uncontrolled | Comorbidity
Item
uncontrolled and/or intercurrent illness
boolean
C0221423 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009488 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnant or breastfeeding females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HIV Infection
Item
known hiv
boolean
C0019693 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial